trial

Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone

NCTId NCT00644852
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 342 (actual)
Sponsored by Johnson & Johnson
Primary completion 2007-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
342 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2007-01
Primary completion
2007-09
Eligibility
ALL

Interventions & indications

Drugs
Retrospective chart review study

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
342
Phase
NA
Primary Completion Date
2007-09
Status
COMPLETED
relationships
The graph out of here
drug
Retrospective chart review study
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication